Comparison · NCT02152631-sae
Abemaciclib vs Erlotinib: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Abemaciclib vs Erlotinib: serious adverse events. Trial comparisons, record NCT02152631-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02152631-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.423 | 0.365 | 0.483 | wilson | |
| Risk in group 2 | 0.246 | 0.188 | 0.315 | wilson | |
| Risk difference, group 1 minus group 2 | 0.177 | 0.087 | 0.26 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.72 | 1.28 | 2.31 | log | |
| Odds ratio, group 1 over group 2 | 2.25 | 1.47 | 3.43 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Abemaciclib than on Erlotinib | 5.65 | 3.84 | 11.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abemaciclib | 200 mg abemaciclib administered, orally, every 12 hours plus BSC on Days 1 to 28 (28 day cycles). | 112 | 265 | EG000 |
| Group 2 | Erlotinib | 150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles). | 43 | 175 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From Baseline to End of Study (Up to 47 Months)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
- NCT number
- NCT02152631
- Phases
- PHASE3
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Abemaciclib, Erlotinib
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2018-12-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02152631?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02152631-sae